▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Dave Williamson

XMFGreenwave4

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Recent Articles by Dave Williamson

Apr 7, 2017 by Dave Williamson

This CEO Had to Go

Apr 7, 2017 by Dave Williamson

The Dow's Down, but Not Roasted

Markets took a dive, but it was nothing compared with one stock's performance.

Apr 7, 2017 by Dave Williamson

1 Biotech Back From the Dead

Apr 7, 2017 by Dave Williamson

1 Biotech Maximizing Shareholder Value

Apr 7, 2017 by Dave Williamson

This Biotech Rejects a Gift Offer

Apr 7, 2017 by Dave Williamson

1 Big Pharma Restocking Its Pipeline

Apr 7, 2017 by Dave Williamson

The Dow Charges Into May

Strong manufacturing data boosts the markets.

Apr 7, 2017 by Dave Williamson

The Dow Ends April With a Whimper

Markets close the month on a down note.

Apr 7, 2017 by Dave Williamson

1 Dividend to Buy, 1 Dividend to Sell

Apr 7, 2017 by Dave Williamson

Is This Biotech Trying to Distract Investors?

Apr 7, 2017 by Dave Williamson

Earnings Fuel the Dow's Surge

Strong earnings resuscitate the markets.

Apr 7, 2017 by Dave Williamson

The Only Reason the Nasdaq Is Soaring

Apple's earnings feed the markets.

Apr 7, 2017 by Dave Williamson

2 Dow Stocks Worth Watching

Apr 7, 2017 by Dave Williamson

Great Earnings Spur the Dow

While the Nasdaq held its breath for Apple's report.

Apr 7, 2017 by Dave Williamson

Europe Craters the Dow

What happens in Europe doesn't stay in Europe.

Apr 7, 2017 by Dave Williamson

3 Biotechs Posting Big Moves

It was a volatile Monday in the land of biotech.

Apr 7, 2017 by Dave Williamson

Will the Dow Finish Strong?

Can earnings help the markets finish the week on an up note?

Apr 7, 2017 by Dave Williamson

2 Biotechs Absolutely Crushing It

Human Genome Sciences' takeover and Gilead's hep-C drug rock.

Apr 7, 2017 by Dave Williamson

No Afternoon Delight for the Dow

Good earnings don't mean the economy has healed.

Apr 7, 2017 by Dave Williamson

The Dow Drops, 2 Stocks Pop

The markets decline after yesterday's rally, but not everyone is down.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services